DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20174391

Unscheduled bleeding on HRT - do we always need to investigate for endometrial pathology?

Ying Yiing Lou, Jeyanthan Kannappar, Sahathevan Sathiyathasan

Abstract


Hormone replacement therapy (HRT) is the most effective method for relieving the effects of hypoestrogenism following menopause. Despite the benefit of the HRT, unscheduled/breakthrough bleeding decreases patients’ compliance with long-term use. The underlying mechanisms for this unpredictable breakthrough bleeding are less well understood. In the event of unscheduled bleeding, investigation may be necessary according to local protocol. Whilst the incidence of underlying benign pathology may be quite high, the likelihood of malignancy is low and unless there is particular clinical concern, these women do not need fast track referral which should be reserved for women with true postmenopausal bleeding.


Keywords


Breakthrough bleeding, Hormone replacement therapy, Menopause, Unscheduled bleeding

Full Text:

PDF

References


Staland B. Continuous treatment with natural estrogens and progestogens, A method to avoid endometrial stimulation. Maturitas. 1981;3:145-6.

Rees M, Stevenson J, Hope S. (Eds.) Management of the menopause: the handbook. 5th edition. London/Marlow: Royal Society of Medicine Press Ltd & British Menopause Society Publications Ltd; 2009.

Hickey M, Elliot J and Davison SL. Hormone replacement therapy. BMJ. 2012;344:e763.

Gebbie AE, Glasier A. and Sweeting V. Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contracept. 1995;52:221-2.

Archer DF, Pickar JH, Bottiglioni F. The Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol. 1994;83:686-92.

Al-Azzawi, Wahab M, Thompson J, Whitehead M, Thompson W. Acceptability and patterns of uterine bleeding in sequential trimegestone-based hormone replacement therapy: a dose-ranging study. Hum Reprod. 1999;14:636-41.

Di Carlo C, Sammartino A, Sardo ADS. Bleeding patterns during con¬tinuous estradiol with different sequential progestogens therapy. Menopause. 2005;12:520-5.

Al-Azzawi F, Habiba M. Regular bleeding on hormone replacement ther¬apy: a myth? Br J Obstet Gynaecol. 1994;101:661-2.

Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-3.

Archer DF. Endometrial bleeding in postmenopausal women: with and without hormone therapy. Menopause. 2011;18:416-20.

Ettinger B, Li DK, Klein R. Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: comparison of cycles versus continuous combined schedules. Fertil Steril. 1998;69:865.

Oosterbaan HP, van Buuren AHJAM, Schram JHN. The effects of continuous combined transdermal oestrogen-progestogen treatment on bleeding patterns and the endometrium in postmenopausal women. Maturitas. 1995;21:211-9.

Nagele F, O’Connor H, Basket TF. Hysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding. Fertil Steril. 1996; 65:1145-50.

Sturdee DW. Irregular bleeding on HRT. Menopause Digest. 1988;5:6-7.

Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1531-43.

Sturdee DW, Ulrich LG, Barlow DH. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. Br J Obstet Gynecol. 2001;107:1392-400.

Cerin A, Heldaas K, Moeller B. Adverse endometrial effects of long cycle estrogen and progestogen replacement therapy. N Engl J Med. 1996;334:668-9.

Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxy-progesterone acetate. Obstet Gynecol. 1994;83:686-92.

Beresford SA, Weiss NS, Voigt LF. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet. 1997;349:458-61.

Whitehead MI, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol. 1990;75:559-76.

Archer DF, Dorin MH, Heine W. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Obstet Gynecol. 1999;94:323-9.

Romer T. Treatment of recurrent bleeding disorders during hormone replacement therapy (HRT) by transcervical endometrial ablation. Gynecol Obstet Invest. 1999;47:255-7.

Dijkhuizen FP, Brolmann HA, Potters AE, Bongers MY, Heintz AP. The accuracy of transvaginal ultrasonography in the diagnosis of endometrial abnormalities. Obstet Gynecol. 1996;87:345-9.

Chien PFW, Voit D, Clark TJ, Khan KS, Gupta JK. Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: A meta-analysis. Acta Obstet Gynecol Scand. In press; 2002.

Granberg S, Ylostalo P, Wikland M, Karlsson B. Endometrial sonographic and histologic features in women with and without hormonal replacement therapy suffering from postmenopausal bleeding. Maturitas. 1997;27:35-40.

Melson L, Hillard TC. The management of abnormal bleeding on HRT - a proposed protocol and early audit of results. J Br Menopause Soc. 2002;4(Suppl. 2).

Etherington IJ, Harrison KR, Read MD. A comparison of outpatient endometrial sampling with hysteroscopy, curettage and cystoscopy in the evaluation of postmenopausal bleeding. J Obstet Gynaecol 1995;15:259-62.

Investigation of post-menopausal bleeding a national clinical guideline. Scottish Intercollegiate Guidelines Network; 2002.

Smith-Bindman R, Kerlikowske K, Feldstein VA, Subak L, Scheidler J, Segal M, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280:1510-7.